{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:40:21Z","timestamp":1783647621200,"version":"3.55.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ekir.2025.03.029","type":"journal-article","created":{"date-parts":[[2025,3,24]],"date-time":"2025-03-24T21:16:10Z","timestamp":1742850970000},"page":"1939-1949","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies"],"prefix":"10.1016","volume":"10","author":[{"given":"Julien","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Solignac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Ferlicot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Mussini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bridoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Huart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Essig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delphine","family":"Campigli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Bobot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Plant\u00e9-Bordeneuve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Sakhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Labeyrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Cauquil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andoni","family":"Echaniz-Laguna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilias","family":"Kounis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Moktefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Devic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mouawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albane","family":"Brodin-Sartorius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renaud","family":"Snanoudj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Zaidan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mie","family":"Jourde-Chiche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.03.029_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.ekir.2025.03.029_bib2","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ekir.2025.03.029_bib3","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.2215\/CJN.08720811","article-title":"Transthyretin amyloidosis and the kidney","volume":"7","author":"Lobato","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.03.029_bib4","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1093\/ndt\/gfad006","article-title":"Pathological spectrum of hereditary transthyretin renal amyloidosis and clinicopathologic correlation: a French observational study","volume":"38","author":"Dang","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.03.029_bib5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/13506129.2022.2098011","article-title":"Natural course and determinants of short-term kidney function decline in hereditary transthyretin amyloidosis: a French observational study","volume":"30","author":"Dang","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2025.03.029_bib6","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1093\/ckj\/sfac118","article-title":"Kidney involvement in hereditary transthyretin amyloidosis: a cohort study of 103 patients","volume":"15","author":"Solignac","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.03.029_bib7","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.03.029_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/ana.24519","article-title":"Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France","volume":"78","author":"Mariani","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.ekir.2025.03.029_bib9","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1111\/ajt.15898","article-title":"The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell\u2013and antibody-mediated rejection","volume":"20","author":"Loupy","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.03.029_bib10","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2025.03.029_bib11","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1056\/NEJMoa070265","article-title":"Natural history and outcome in systemic AA amyloidosis","volume":"356","author":"Lachmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.029_bib12","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"AL amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.ekir.2025.03.029_bib13","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/brain\/75.3.408","article-title":"A peculiar form of peripheral neuropathyfamiliar atypical generalized amyloidosis with special involvement of the peripheral nerves","volume":"75","author":"Andrade","year":"1952","journal-title":"Brain"},{"key":"10.1016\/j.ekir.2025.03.029_bib14","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3390\/brainsci11080980","article-title":"Renal involvement in hereditary transthyretin amyloidosis: an Italian single-centre experience","volume":"11","author":"Ferraro","year":"2021","journal-title":"Brain Sci"},{"key":"10.1016\/j.ekir.2025.03.029_bib15","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ejhf.3094","article-title":"Albuminuria in transthyretin cardiac amyloidosis: prevalence, progression and prognostic importance","volume":"26","author":"Ioannou","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ekir.2025.03.029_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/clc.24298","article-title":"Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis","volume":"47","author":"McDonald","year":"2024","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.ekir.2025.03.029_bib17","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.mayocp.2019.02.012","article-title":"Renal infarction and its consequences for renal function in patients with cardiac amyloidosis","volume":"94","author":"Dang","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2025.03.029_bib18","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1093\/ndt\/18.3.532","article-title":"Familial ATTR amyloidosis: microalbuminuria as a predictor of symptomatic disease and clinical nephropathy","volume":"18","author":"Lobato","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.03.029_bib19","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1053\/ajkd.1998.v31.pm9631837","article-title":"Familial amyloid polyneuropathy type I (Portuguese): distribution and characterization of renal amyloid deposits","volume":"31","author":"Lobato","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.03.029_bib20","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gfh063","article-title":"Changes in renal function in patients with familial amyloid polyneuropathy treated with orthotopic liver transplantation","volume":"19","author":"Snanoudj","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.03.029_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506120600722662","article-title":"Value of renal biopsy in the prognosis of liver transplantation in familial amyloid polyneuropathy ATTR Val30Met patients","volume":"13","author":"Oguchi","year":"2006","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2025.03.029_bib22","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMra2200923","article-title":"Liver transplantation","volume":"389","author":"Lucey","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.029_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1600-6143.2006.01585.x","article-title":"Progressive wild-type transthyretin deposition after liver transplantation preferentially occurs onto myocardium in FAP patients","volume":"7","author":"Yazaki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2025.03.029_bib24","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1007\/s40620-021-01127-6","article-title":"Peri-operative risk factors of chronic kidney disease after liver transplantation","volume":"35","author":"Chopinet","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.03.029_bib25","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.029_bib26","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaccao.2024.02.007","article-title":"Effect of tafamidis on renal function in patients with transthyretin amyloid cardiomyopathy in ATTR-ACT","volume":"6","author":"Sperry","year":"2024","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.ekir.2025.03.029_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/13506129.2016.1277697","article-title":"Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule","volume":"24","author":"Rocha","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2025.03.029_bib28","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1080\/13506129.2019.1583186","article-title":"Significant reduction in proteinuria after treatment with tafamidis","volume":"26","author":"Ferrer-Nadal","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2025.03.029_bib29","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/13506129.2019.1600497","article-title":"Tafamidis dramatically improved severe proteinuria in a patient with TTR V30M hereditary ATTR amyloidosis","volume":"26","author":"Ikeda","year":"2019","journal-title":"Amyloid"},{"key":"10.1016\/j.ekir.2025.03.029_bib30","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1716793","article-title":"Inotersen treatment for patients with hereditary transthyretin amyloidosis","volume":"379","author":"Benson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.03.029_bib31","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1053\/j.ajkd.2022.08.018","article-title":"Focal segmental glomerulosclerosis complicating therapy with inotersen, an antisense oligonucleotide inhibitor: a case report","volume":"81","author":"Law","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2025.03.029_bib32","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3390\/genes13122236","article-title":"Trajectories of kidney function in patients with ATTRv treated with gene silencers","volume":"13","author":"Luigetti","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ekir.2025.03.029_bib33","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.03.029_bib34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jcmg.2020.07.043","article-title":"Reduction in CMR derived extracellular volume with patisiran indicates cardiac amyloid regression","volume":"14","author":"Fontana","year":"2021","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.ekir.2025.03.029_bib35","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1016\/j.jacc.2024.03.429","article-title":"SGLT2 inhibitor therapy in patients with transthyretin amyloid cardiomyopathy","volume":"83","author":"Porcari","year":"2024","journal-title":"J Am Coll Cardiol"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492500172X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S246802492500172X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T15:27:19Z","timestamp":1752766039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S246802492500172X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S246802492500172X"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.03.029","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kidney Outcomes in Patients With Hereditary Transthyretin Amyloid Nephropathy Treated With Transthyretin Stabilizers And Gene-Silencer Therapies","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.03.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.04.050","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}